PTPRC and cancer: In the current study, cell counts of CD45+, CD3+ T, CD3+CD4+ Th, CD3+CD8+ CTL, CD16+CD56+ NK and CD19+ B sharply decreased not only with the cancer diagnosis, but also with the tumor moving toward advanced stage.